Lv3
320 积分 2025-11-26 加入
Progress in Targeting the Untouchables: Emerging Approaches for Hard-to-Drug Cancer Targets
23天前
已关闭
Current advances and development strategies of orally bioavailable PROTACs
1个月前
已完结
An overview of KRAS G12D inhibitors: Expanding the therapeutic frontier of KRAS in targeting KRAS G12D using diverse therapeutic modalities
1个月前
已完结
RAS mutation–specific responses to paralog- and state-selective RAS inhibitors
1个月前
已完结
Menin inhibitors for adult acute myeloid leukemia: 2025 update
1个月前
已完结
The MEK–RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers
1个月前
已完结
A molecular glue halts RAS–MAPK signaling
1个月前
已完结
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer Therapy
1个月前
已完结
Discovery of PKMYT1 Inhibitors with a Novel Scaffold for the Treatment of Triple-Negative Breast Cancer
1个月前
已完结
Discovery of Bis-Acyl Hydrazides as Potent and Bioavailable MTA-Cooperative PRMT5 Inhibitors: A Case Study of Leveraging the Deuterium Kinetic Isotope Effect
1个月前
已完结
皖公网安备34019202002308
